Atea Pharmaceuticals

AVIR

Market cap $433M

5.41 USD

-0.02

0.37%

At close Updated May 11, 4:00 PM EDT

Pre-market

After hours

5.51

+0.10

1.85%

1 day

-0.37%

5 days

-5.58%

1 month

-5.25%

3 months

21.3%

6 months

60.06%

Year to date

55.46%

1 year

82.77%

5 years

-73.85%

10 years

-82.17%

About: Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Employees: 55

Healthcare Biotechnology